A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant

Hepatology

Volumn 57, Issue 3, 2013, Pages 985-994

  Sureau, Camille ^a,b   Salisse, Jessica ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; ENVELOPE PROTEIN; HEPARAN SULFATE; PROLINE; PROTEOGLYCAN; ALANINAL; DETERGENT; DRUG DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; IMMOBILIZED PROTEIN; TRYPSIN; VIRUS ENVELOPE PROTEIN;

ANTIGENICITY; ARTICLE; BINDING SITE; CELL SURFACE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS INFECTIVITY; VIRUS PARTICLE; AMINO ACID SUBSTITUTION; CHEMISTRY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIRION; VIROLOGY;

ALANINE; AMINO ACID SUBSTITUTION; BINDING SITES; DETERGENTS; HEPARITIN SULFATE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMOBILIZED PROTEINS; PROTEIN STRUCTURE, TERTIARY; TRYPSIN; VIRAL ENVELOPE PROTEINS; VIRION;

MLCS; MLOWN;

EID: 84874486107     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26125     Document Type: Article

References (37)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
2. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007; 13: 22-38.
3. Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986; 58: 945-950.
4. Wang CJ, Chen PJ, Wu JC, Patel D, Chen DS. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. J Virol 1991; 65: 6630-6636.
5. Sureau C, Lanford R. Analysis of hepatitis B virus envelope proteins in assembly and infectivity of human hepatitis delta virus. Prog Clin Biol Res 1993; 382: 45-51.
6. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984; 52: 396-402.
7. Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009; 83: 12443-12451.
8. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. HEPATOLOGY 2006; 43: 750-760.
9. Salisse J, Sureau C. A function essential to viral entry underlies the hepatitis B virus "a" determinant. J Virol 2009; 83: 9321-9328.
10. Sureau C, Jacob JR, Eichberg JW, Lanford RE. Tissue culture system for infection with human hepatitis delta virus. J Virol 1991; 65: 3443-3450.
11. Sureau C. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Methods Mol Biol 2010; 640: 463-473.
12. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
13. Abou-Jaoude G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007; 81: 13057-13066.
14. Zahn A, Allain JP. Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005; 86: 677-685.
15. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008; 10: 122-133.
16. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. HEPATOLOGY 2007; 46: 1759-1768.
17. Chai N, Chang HE, Nicolas E, Han Z, Jarnik M, Taylor J. Properties of subviral particles of hepatitis B virus. J Virol 2008; 82: 7812-7817.
18. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 2011; 3.
19. Blanchet M, Sureau C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J Virol 2007; 81: 5841-5849.
20. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99: 15655-15660.
21. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(Suppl. 1): 11-20.
22. Sureau C, Fournier-Wirth C, Maurel P. Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus. J Virol 2003; 77: 5519-5523.
23. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
24. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. HEPATOLOGY 2001; 34: 385-394.
25. Stibbe W, Gerlich WH. Characterization of pre-s gene products in hepatitis B surface antigen. Dev Biol Stand 1983; 54: 33-43.
26. Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, et al. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J Struct Biol 2009; 165: 146-156.
27. Esko JD, Linhardt RJ. Proteins that bind sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al, editors. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
28. Wounderlich G, Bruss V. Characterization of early hepatitis B virus surface protein oligomers. Arch Virol 1996; 141: 1191-1205.
29. Mulder AM, Carragher B, Towne V, Meng Y, Wang Y, Dieter L, et al. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PLoS One 2012; 7: e33235.
30. Short JM, Chen S, Roseman AM, Butler PJ, Crowther RA. Structure of hepatitis B surface antigen from subviral tubes determined by electron cryomicroscopy. J Mol Biol 2009; 390: 135-141.
31. Seitz S, Urban S, Antoni C, Bottcher B. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J 2007; 26: 4160-4167.
32. Foley EM, Esko JD. Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins. Prog Mol Biol Transl Sci 2010; 93: 213-233.
33. Galibert F, Chen TN, Mandart E. Nucleotide sequence of a cloned woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol 1982; 41: 51-65.
34. Cote PJ Jr, Gerin JL. Nonoverlapping antigenic sites of woodchuck hepatitis virus surface antigen and their cross-reactivity with ground squirrel hepatitis virus and hepatitis B virus surface antigens. J Virol 1983; 47: 15-23.
35. Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Sulfated polyanions do not inhibit duck hepatitis B virus infection. Antimicrob Agents Chemother 1991; 35: 2431-2433.
36. Heermann KH, Gerlich WH. Surface proteins of hepatitis B viruses. In: Maclachlan A, ed. Molecular Biology of the Hepatitis B Virus. Boca Raton, FL: CRC Press; 1991: 109-144.
37. Shearer MH, Sureau C, Dunbar B, Kennedy RC. Structural characterization of viral neutralizing monoclonal antibodies to hepatitis B surface antigen. Mol Immunol 1998; 35: 1149-1160.